-
1
-
-
84872967522
-
Cancer statistics, 2013
-
Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA: Cancer J Clin 2013, 63:11-30.
-
(2013)
CA: Cancer J Clin
, vol.63
, pp. 11-30
-
-
Siegel, R.1
Naishadham, D.2
Jemal, A.3
-
2
-
-
84863250697
-
Survival rates for International Federation of Gynecology and Obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review
-
Seidman J.D., Yemelyanova A., Cosin J.A., Smith A., Kurman R.J. Survival rates for International Federation of Gynecology and Obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review. Int J Gynecol Cancer 2012, 22:367-371.
-
(2012)
Int J Gynecol Cancer
, vol.22
, pp. 367-371
-
-
Seidman, J.D.1
Yemelyanova, A.2
Cosin, J.A.3
Smith, A.4
Kurman, R.J.5
-
3
-
-
84857793524
-
Decisions about dendritic cells: past, present, and future
-
Steinman R.M. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012, 30:1-22.
-
(2012)
Annu Rev Immunol
, vol.30
, pp. 1-22
-
-
Steinman, R.M.1
-
4
-
-
79955630348
-
Engineering dendritic cells to enhance cancer immunotherapy
-
Boudreau J.E., Bonehill A., Thielemans K., Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther 2011, 19:841-853.
-
(2011)
Mol Ther
, vol.19
, pp. 841-853
-
-
Boudreau, J.E.1
Bonehill, A.2
Thielemans, K.3
Wan, Y.4
-
5
-
-
2942559009
-
Cancer immunotherapy with mRNA-transfected dendritic cells
-
Gilboa E., Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004, 199:251-263.
-
(2004)
Immunol Rev
, vol.199
, pp. 251-263
-
-
Gilboa, E.1
Vieweg, J.2
-
6
-
-
84892996730
-
Design of an optimized Wilms' tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo
-
Benteyn D., Anguille S., Van Lint S., Heirman C., Van Nuffel A.M., Corthals J., et al. Design of an optimized Wilms' tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo. Mol Ther Nucleic Acids 2013, 2:e134.
-
(2013)
Mol Ther Nucleic Acids
, vol.2
-
-
Benteyn, D.1
Anguille, S.2
Van Lint, S.3
Heirman, C.4
Van Nuffel, A.M.5
Corthals, J.6
-
7
-
-
84885981323
-
Exploiting dendritic cells in the development of cancer vaccines
-
Bracci L., Capone I., Moschella F., Proietti E., Belardelli F. Exploiting dendritic cells in the development of cancer vaccines. Expert Rev Vaccines 2013, 12:1195-1210.
-
(2013)
Expert Rev Vaccines
, vol.12
, pp. 1195-1210
-
-
Bracci, L.1
Capone, I.2
Moschella, F.3
Proietti, E.4
Belardelli, F.5
-
8
-
-
84869175164
-
Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review
-
Tanyi J.L., Chu C.S. Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review. Immunotherapy 2012, 4:995-1009.
-
(2012)
Immunotherapy
, vol.4
, pp. 995-1009
-
-
Tanyi, J.L.1
Chu, C.S.2
-
9
-
-
54249126862
-
Gene therapy using adeno-associated virus vectors
-
Daya S., Berns K.I. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008, 21:583-593.
-
(2008)
Clin Microbiol Rev
, vol.21
, pp. 583-593
-
-
Daya, S.1
Berns, K.I.2
-
10
-
-
0036147989
-
Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells
-
Chiriva-Internati M., Liu Y., Salati E., Zhou W., Wang Z., Grizzi F., et al. Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol 2002, 32:30-38.
-
(2002)
Eur J Immunol
, vol.32
, pp. 30-38
-
-
Chiriva-Internati, M.1
Liu, Y.2
Salati, E.3
Zhou, W.4
Wang, Z.5
Grizzi, F.6
-
11
-
-
0034856182
-
Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy
-
Ponnazhagan S., Mahendra G., Curiel D.T., Shaw D.R. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol 2001, 75:9493-9501.
-
(2001)
J Virol
, vol.75
, pp. 9493-9501
-
-
Ponnazhagan, S.1
Mahendra, G.2
Curiel, D.T.3
Shaw, D.R.4
-
12
-
-
34248395538
-
Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2
-
Veron P., Allo V., Riviere C., Bernard J., Douar A-M., Masurier C. Major subsets of human dendritic cells are efficiently transduced by self-complementary adeno-associated virus vectors 1 and 2. J Virol 2007, 81:5385-5394.
-
(2007)
J Virol
, vol.81
, pp. 5385-5394
-
-
Veron, P.1
Allo, V.2
Riviere, C.3
Bernard, J.4
Douar, A.-M.5
Masurier, C.6
-
13
-
-
29244438789
-
Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands
-
Aldrich W., Ren C., White A., Zhou S., Kumar S., Jenkins C., et al. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands. Gene Ther 2005, 13:29-39.
-
(2005)
Gene Ther
, vol.13
, pp. 29-39
-
-
Aldrich, W.1
Ren, C.2
White, A.3
Zhou, S.4
Kumar, S.5
Jenkins, C.6
-
14
-
-
78650082356
-
Optimized transduction of human monocyte-derived dendritic cells by recombinant adeno-associated virus serotype 6
-
Ussher J.E., Taylor J.A. Optimized transduction of human monocyte-derived dendritic cells by recombinant adeno-associated virus serotype 6. Hum Gene Ther 2010, 21:1675-1686.
-
(2010)
Hum Gene Ther
, vol.21
, pp. 1675-1686
-
-
Ussher, J.E.1
Taylor, J.A.2
-
15
-
-
84893872048
-
Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy
-
Pandya J., Ortiz L., Ling C., Rivers A.E., Aslanidi G. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol Cell Biol 2013.
-
(2013)
Immunol Cell Biol
-
-
Pandya, J.1
Ortiz, L.2
Ling, C.3
Rivers, A.E.4
Aslanidi, G.5
-
16
-
-
84864380076
-
MAGE-A antigens as targets in tumour therapy
-
Meek D.W., Marcar L. MAGE-A antigens as targets in tumour therapy. Cancer Lett 2012, 324:126-132.
-
(2012)
Cancer Lett
, vol.324
, pp. 126-132
-
-
Meek, D.W.1
Marcar, L.2
-
17
-
-
35748979692
-
Immunological profiling of a panel of human ovarian cancer cell lines
-
Carr T.M., Adair S.J., Fink M.J., Hogan K.T. Immunological profiling of a panel of human ovarian cancer cell lines. Cancer Immunol Immunother 2008, 57:31-42.
-
(2008)
Cancer Immunol Immunother
, vol.57
, pp. 31-42
-
-
Carr, T.M.1
Adair, S.J.2
Fink, M.J.3
Hogan, K.T.4
-
18
-
-
77951222450
-
Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines
-
Zhang S., Zhou X., Yu H., Yu Y. Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer 2010, 10:163.
-
(2010)
BMC Cancer
, vol.10
, pp. 163
-
-
Zhang, S.1
Zhou, X.2
Yu, H.3
Yu, Y.4
-
19
-
-
22144476522
-
Hematopoietic stem cell transduction by recombinant adeno-associated virus vectors: problems and solutions
-
Srivastava A. Hematopoietic stem cell transduction by recombinant adeno-associated virus vectors: problems and solutions. Hum Gene Ther 2005, 16:792-798.
-
(2005)
Hum Gene Ther
, vol.16
, pp. 792-798
-
-
Srivastava, A.1
-
20
-
-
27544514423
-
Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma
-
Batchu R.B., Moreno A.M., Szmania S.M., Bennett G., Spagnoli G.C., Ponnazhagan S., et al. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res 2005, 65:10041-10049.
-
(2005)
Cancer Res
, vol.65
, pp. 10041-10049
-
-
Batchu, R.B.1
Moreno, A.M.2
Szmania, S.M.3
Bennett, G.4
Spagnoli, G.C.5
Ponnazhagan, S.6
-
21
-
-
0034663292
-
High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH
-
Shaughnessy J., Tian E., Sawyer J., Bumm K., Landes R., Badros A., et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000, 96:1505-1511.
-
(2000)
Blood
, vol.96
, pp. 1505-1511
-
-
Shaughnessy, J.1
Tian, E.2
Sawyer, J.3
Bumm, K.4
Landes, R.5
Badros, A.6
-
22
-
-
84892998510
-
Intra-and intertumoral variation in the expression of cancer testis antigens, MAGE-3 and NY-ESO-1 in multiple myeloma
-
Gupta S., Pei L., Droojenbroeck J., Szmania S., Yacobby S., Batchu R., et al. Intra-and intertumoral variation in the expression of cancer testis antigens, MAGE-3 and NY-ESO-1 in multiple myeloma. Blood 2002, 2002.
-
(2002)
Blood
, pp. 2002
-
-
Gupta, S.1
Pei, L.2
Droojenbroeck, J.3
Szmania, S.4
Yacobby, S.5
Batchu, R.6
-
23
-
-
20844432364
-
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses
-
Van Rhee F., Szmania S.M., Zhan F., Gupta S.K., Pomtree M., Lin P., et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005, 105:3939-3944.
-
(2005)
Blood
, vol.105
, pp. 3939-3944
-
-
Van Rhee, F.1
Szmania, S.M.2
Zhan, F.3
Gupta, S.K.4
Pomtree, M.5
Lin, P.6
-
24
-
-
10744225491
-
High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector
-
Batchu R., Moreno A., Szmania S., Gupta S., Zhan F., Rosen N., et al. High-level expression of cancer/testis antigen NY-ESO-1 and human granulocyte-macrophage colony-stimulating factor in dendritic cells with a bicistronic retroviral vector. Hum Gene Ther 2003, 14:1333-1345.
-
(2003)
Hum Gene Ther
, vol.14
, pp. 1333-1345
-
-
Batchu, R.1
Moreno, A.2
Szmania, S.3
Gupta, S.4
Zhan, F.5
Rosen, N.6
-
25
-
-
77958102381
-
Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle
-
Qiao C., Zhang W., Yuan Z., Shin J-H., Li J., Jayandharan G.R., et al. Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. Hum Gene Ther 2010, 21:1343-1348.
-
(2010)
Hum Gene Ther
, vol.21
, pp. 1343-1348
-
-
Qiao, C.1
Zhang, W.2
Yuan, Z.3
Shin, J.-H.4
Li, J.5
Jayandharan, G.R.6
-
26
-
-
29444442811
-
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
-
Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. PNAS 2005, 102:18538-18543.
-
(2005)
PNAS
, vol.102
, pp. 18538-18543
-
-
Sato, E.1
Olson, S.H.2
Ahn, J.3
Bundy, B.4
Nishikawa, H.5
Qian, F.6
-
27
-
-
0037448353
-
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
-
Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
-
(2003)
N Engl J Med
, vol.348
, pp. 203-213
-
-
Zhang, L.1
Conejo-Garcia, J.R.2
Katsaros, D.3
Gimotty, P.A.4
Massobrio, M.5
Regnani, G.6
-
28
-
-
82455175361
-
MAGE-A family: attractive targets for cancer immunotherapy
-
Sang M., Lian Y., Zhou X., Shan B. MAGE-A family: attractive targets for cancer immunotherapy. Vaccine 2011, 29:8496-8500.
-
(2011)
Vaccine
, vol.29
, pp. 8496-8500
-
-
Sang, M.1
Lian, Y.2
Zhou, X.3
Shan, B.4
-
29
-
-
84880730418
-
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
-
Kruit W.H., Suciu S., Dreno B., Mortier L., Robert C., Chiarion-Sileni V., et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 2013, 31:2413-2420.
-
(2013)
J Clin Oncol
, vol.31
, pp. 2413-2420
-
-
Kruit, W.H.1
Suciu, S.2
Dreno, B.3
Mortier, L.4
Robert, C.5
Chiarion-Sileni, V.6
-
30
-
-
42549106307
-
Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)
-
Vansteenkiste J., Zielinski M., Linder A., Dahabre J., Esteban E., Malinowski W., et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007, 25:7554.
-
(2007)
J Clin Oncol
, vol.25
, pp. 7554
-
-
Vansteenkiste, J.1
Zielinski, M.2
Linder, A.3
Dahabre, J.4
Esteban, E.5
Malinowski, W.6
-
31
-
-
33746707463
-
Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 ovarian cancer cell lines
-
Imura M., Yamashita S., Cai L.Y., Furuta J., Wakabayashi M., Yasugi T., et al. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 ovarian cancer cell lines. Cancer Lett 2006, 241:213-220.
-
(2006)
Cancer Lett
, vol.241
, pp. 213-220
-
-
Imura, M.1
Yamashita, S.2
Cai, L.Y.3
Furuta, J.4
Wakabayashi, M.5
Yasugi, T.6
-
32
-
-
79954455826
-
Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103
-
Moreno-Bost A., Szmania S., Stone K., Garg T., Hoerring A., Szymonifka J., et al. Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy 2011, 13:618-628.
-
(2011)
Cytotherapy
, vol.13
, pp. 618-628
-
-
Moreno-Bost, A.1
Szmania, S.2
Stone, K.3
Garg, T.4
Hoerring, A.5
Szymonifka, J.6
-
33
-
-
59449088943
-
Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules
-
Adair S.J., Hogan K.T. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother 2009, 58:589-601.
-
(2009)
Cancer Immunol Immunother
, vol.58
, pp. 589-601
-
-
Adair, S.J.1
Hogan, K.T.2
-
34
-
-
84856520424
-
Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials
-
Wang Z., Tapscott S.J., Chamberlain J.S., Storb R. Immunity and AAV-mediated gene therapy for muscular dystrophies in large animal models and human trials. Front Microbiol 2011, 2:201.
-
(2011)
Front Microbiol
, vol.2
, pp. 201
-
-
Wang, Z.1
Tapscott, S.J.2
Chamberlain, J.S.3
Storb, R.4
-
35
-
-
78650239955
-
Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic toll-like receptor agonists
-
Triozzi P.L., Aldrich W., Ponnazhagan S. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic toll-like receptor agonists. Vaccine 2010, 28:7837-7843.
-
(2010)
Vaccine
, vol.28
, pp. 7837-7843
-
-
Triozzi, P.L.1
Aldrich, W.2
Ponnazhagan, S.3
-
36
-
-
75449109000
-
Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34+ peripheral blood progenitor cells
-
Veldwijk M.R., Sellner L., Stiefelhagen M., Kleinschmidt J.A., Laufs S., Topaly J., et al. Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34+ peripheral blood progenitor cells. Cytotherapy 2010, 12:107-112.
-
(2010)
Cytotherapy
, vol.12
, pp. 107-112
-
-
Veldwijk, M.R.1
Sellner, L.2
Stiefelhagen, M.3
Kleinschmidt, J.A.4
Laufs, S.5
Topaly, J.6
-
37
-
-
84892967754
-
Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo
-
Song L., Kauss M.A., Kopin E., Chandra M., Ul-Hasan T., Miller E., et al. Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo. Cytotherapy 2013, 15:986-998.
-
(2013)
Cytotherapy
, vol.15
, pp. 986-998
-
-
Song, L.1
Kauss, M.A.2
Kopin, E.3
Chandra, M.4
Ul-Hasan, T.5
Miller, E.6
-
38
-
-
16844379997
-
Immunosuppressive networks in the tumour environment and their therapeutic relevance
-
Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5:263-274.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 263-274
-
-
Zou, W.1
-
39
-
-
80655142485
-
Continuous CD8+ T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery
-
Xu D., Walker C.M. Continuous CD8+ T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery. J Virol 2011, 85:12083-12086.
-
(2011)
J Virol
, vol.85
, pp. 12083-12086
-
-
Xu, D.1
Walker, C.M.2
-
40
-
-
77954870211
-
Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity
-
Jensen S.S., Gad M. Differential induction of inflammatory cytokines by dendritic cells treated with novel TLR-agonist and cytokine based cocktails: targeting dendritic cells in autoimmunity. J Inflamm (Lond) 2010, 7:37.
-
(2010)
J Inflamm (Lond)
, vol.7
, pp. 37
-
-
Jensen, S.S.1
Gad, M.2
-
41
-
-
79151477008
-
Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery
-
Driessens G., Nuttin L., Gras A., Maetens J., Mievis S., Schoore M., et al. Development of a successful antitumor therapeutic model combining in vivo dendritic cell vaccination with tumor irradiation and intratumoral GM-CSF delivery. Cancer Immunol Immunother 2011, 60:273-281.
-
(2011)
Cancer Immunol Immunother
, vol.60
, pp. 273-281
-
-
Driessens, G.1
Nuttin, L.2
Gras, A.3
Maetens, J.4
Mievis, S.5
Schoore, M.6
|